Novel therapeutics for the management of castration-resistant prostate cancer (CRPC)

BJU International

Volumn 109, Issue 7, 2012, Pages 968-985

  Lee, Daniel J ^a   Cha, Eugene K ^a   Dubin, Justin M ^a   Beltran, Himisha ^a   Chromecki, Thomas F ^a,b   Fajkovic, Harun ^a,c   Scherr, Douglas S ^a   Tagawa, Scott T ^a   Shariat, Shahrokh F ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c General Hospital St Poelten   (Austria)

Author keywords

castration resistant prostate cancer; cytotoxic agents; docetaxel; first line therapy; prostate specific antigen; second line therapy

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANTINEOPLASTIC AGENT; BCL 2 INHIBITOR; BEVACIZUMAB; BIOLOGICAL MARKER; CABAZITAXEL; CALCITRIOL; CUSTIRSEN; CYTOTOXIC AGENT; DEXAMETHASONE; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; EPOTHILONE DERIVATIVE; ERIBULIN; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; MITOXANTRONE; OBLIMERSEN; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SIPULEUCEL T; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR INHIBITOR;

ALLERGIC DISEASE; ANDROGEN DEPRIVATION THERAPY; ANEMIA; AORTA DISSECTION; ARTHRALGIA; BACKACHE; BACTEREMIA; BEDTIME DOSAGE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROVASCULAR ACCIDENT; CHILL; CIRCULATING TUMOR CELL; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; FATIGUE; FEBRILE NEUTROPENIA; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; INFECTION; INFLUENZA; ISCHEMIA; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; METASTASIS; MICROMETASTASIS; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGOR; SEIZURE; SEPTIC SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TYPHLITIS; ULCER; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 84858441614     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10643.x     Document Type: Review

References (110)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Macfarlane R, Chi K,. Novel targeted therapies for prostate cancer. Urol Clin North Am 2010; 37: 105-19
3. Shariat SF, Scardino PT, Lilja H,. Screening for prostate cancer: an update. Can J Urol 2008; 15: 4363-74
4. Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT,. Critical review of prostate cancer predictive tools. Future Oncol 2009; 5: 1555-84
5. Harzstark A, Small E,. Castrate-resistant prostate cancer: therapeutic strategies. Expert Opin Pharmacother 2010; 11: 937-45
6. Lassi K, Dawson N,. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21: 260-5
7. Shariat SF, Canto EI, Kattan MW, Slawin KM,. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004; 6: 58-72
8. Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH,. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009; 69: 1579-85
9. Scher H, Halabi S, Tannock I, et al,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-59
10. Hussain M, Goldman B, Tangen C, et al,. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 2450-6
11. Thalmann GN, Sikes RA, Chang SM, Johnston DA, von Eschenbach AC, Chung LW,. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 1996; 88: 794-801 (Pubitemid 26187388)
12. Dixon SC, Knopf KB, Figg WD,. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001; 53: 73-91 (Pubitemid 32173108)
13. Fleming MT, Morris MJ, Heller G, Scher HI,. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 2006; 3: 658-67 (Pubitemid 44843124)
14. Bubley G, Carducci M, Dahut W, et al,. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-7 (Pubitemid 29517916)
15. Dehdashti F, Picus J, Michalski J, et al,. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005; 32: 344-50 (Pubitemid 40562127)
16. Scher H, Beer T, Higano C, et al,. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-46
17. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P,. PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med 2011; 41: 29-44
18. de Bono JS, Scher HI, Montgomery RB, et al,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9
19. Attard G, Reid A, de Bono J,. Abiraterone acetate is well tolerated without concomitant use of corticosteroids. J Clin Oncol 2010; 28: e560-1; author reply e562
20. Stott S, Lee R, Nagrath S, et al,. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med 2010; 2: 25ra3
21. Gleghorn J, Pratt E, Denning D, et al,. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 2010; 10: 27-9
22. Petrylak D, Tangen C, Hussain M, et al,. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)
23. Tannock I, de Wit R, Berry W, et al,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
24. Dahut W, Gulley J, Arlen P, et al,. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2532-9 (Pubitemid 41103740)
25. Ning Y, Gulley J, Arlen P, et al,. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 2070-6
26. Beer T, Ryan C, Venner P, et al,. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007; 25: 669-74 (Pubitemid 350002922)
27. Beer TM, Ryan CW, Venner PM, et al,. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008; 112: 326-30
28. Scher HI, Jia X, Chi K, et al,. Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer. J Clin Oncol 2011; 29: 2191-8
29. Tolcher A, Chi K, Kuhn J, et al,. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 3854-61 (Pubitemid 40685606)
30. Sternberg C, Dumez H, Van Poppel H, et al,. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 1264-9
31. Chi KN, Hotte SJ, Yu EY, et al,. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 4247-54
32. Picus J, Halabi S, Kelly WK, et al,. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer 2011; 117: 526-33
33. Higano C, Corman J, Smith D, et al,. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113: 975-84
34. Small E, Sacks N, Nemunaitis J, et al,. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 3883-91 (Pubitemid 47037595)
35. Kantoff PW, Higano CS, Shore ND, et al,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22
36. Higano C, Schellhammer P, Small E, et al,. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115: 3670-9
37. Small E, Schellhammer P, Higano C, et al,. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24: 3089-94 (Pubitemid 46638945)
38. James N, Caty A, Borre M, et al,. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-23
39. Yu E, Wilding G, Posadas E, et al,. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-8
40. Araujo J, Armstrong AJ, Braud EL, et al,. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009; 27 (Suppl.): abstract 5061 (Meeting Abstracts)
41. 177Lu-J591) in patients (pts) with metastatic castrate-resistant prostate cancer (metCRPC). J Clin Oncol 2008; 26: 5140
42. Ryan CJ, Smith MR, Fong L, et al,. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28: 1481-8
43. Attard G, Reid AH, A'Hern R, et al,. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8
44. Sternberg C, Whelan P, Hetherington J, et al,. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 2005; 68: 2-9 (Pubitemid 40675002)
45. Oh W, Halabi S, Kelly W, et al,. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: cancer and Leukemia Group B 99813. Cancer 2003; 98: 2592-8 (Pubitemid 37509522)
46. Petrioli R, Paolelli L, Francini E, Manganelli A, Salvestrini F, Francini G,. Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer. Urology 2007; 69: 142-6 (Pubitemid 46161681)
47. Figg WD, Woo S, Zhu W, et al,. A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol 2010; 183: 2219-26
48. Petrylak DP, Resto-Garces K, Tibyan M, Mohile SG,. A phase I open-label study using lenalidomide and docetaxel in castration-resistant prostate cancer. J Clin Oncol 2009; 27 (Suppl.): 272s (abstract 5156)
49. Schwartz G, Oeler T, UskokoviÄ M, Bahnson R,. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994; 14: 1077-81 (Pubitemid 24272570)
50. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY,. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005; 7: 909-15 (Pubitemid 41486292)
51. Poon S, Easterbrook-Smith SB, Rybchyn MS, Carver JA, Wilson MR,. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 2000; 39: 15953-60 (Pubitemid 32038257)
52. Zoubeidi A, Ettinger S, Beraldi E, et al,. Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells. Mol Cancer Res 2010; 8: 119-30
53. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME,. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179-88 (Pubitemid 34137445)
54. Miyake H, Nelson C, Rennie PS, Gleave ME,. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 170-6 (Pubitemid 30058748)
55. George D, Halabi S, Shepard T, et al,. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-6 (Pubitemid 32994827)
56. Shariat S, Anwuri V, Lamb D, Shah N, Wheeler T, Slawin K,. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004; 22: 1655-63 (Pubitemid 41079804)
57. Kelly W, Halabi S, Carducci D, et al,. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010; 28: 18s
58. Mani S, Macapinlac MJ, Goel S, et al,. The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 2004; 15: 553-8 (Pubitemid 38932321)
59. Kelly W,. Epothilones in prostate cancer. Urol Oncol 2011; 29: 358-65
60. Hussain M, Tangen C, Lara PJ, et al,. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23: 8724-9 (Pubitemid 46211517)
61. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR,. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 492-7
62. Beer TM, Smith DC, Hussain A, et al,. Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2009; 27 (Suppl.): abstract 5059 (Meeting Abstracts)
63. Graff J, Smith DC, Neerukonda L, et al,. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC). J Clin Oncol 2008; 26 (Suppl.): abstract 5141
64. de Bono JS, Maroto P, Calvo E, et al,. Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy. Genitourinary Cancer Symposium 2009. Available at
65. Small E, Demkow T, Gerritsen WR, et al,. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at
66. Higano C, Saad F, Somer B, et al,. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer. Genitourinary Cancer Symposium 2009. Available at
67. Beer TM, Slovin SF, Higano CS, et al,. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008; 26 (Suppl.): abstr 5004
68. Fong L, Kwek SS, O'Brien S, et al,. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-15
69. Nelson J, Hedican S, George D, et al,. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-9
70. Carducci M, Saad F, Abrahamsson P, et al,. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-66 (Pubitemid 350036854)
71. Meng Y, Tang W, Dai Y, et al,. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther 2008; 7: 2192-202
72. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B,. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009; 15: 3172-6
73. Sonpavde G, Periman PO, Bernold D, et al,. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-24
74. Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T,. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010; 9: 107
75. Israeli R, Powell C, Corr J, Fair W, Heston W,. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807-11 (Pubitemid 24116191)
76. Bostwick D, Pacelli A, Blute M, Roche P, Murphy G,. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-61 (Pubitemid 28240834)
77. Milowsky M, Nanus D, Kostakoglu L, Vallabhajosula S, Goldsmith S, Bander N,. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2522-31 (Pubitemid 41103739)
78. Milowsky MI, Nanus DM, Kostakoglu L, et al,. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007; 25: 540-7 (Pubitemid 350002961)
79. Bander N, Milowsky M, Nanus D, Kostakoglu L, Vallabhajosula S, Goldsmith S,. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23: 4591-601 (Pubitemid 46224061)
80. 177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J Clin Oncol 2010; 28: 4667
81. Tagawa ST, Beltran H, Vallabhajosula S, et al,. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010; 116: 1075-83
82. 177Lu -J591 for Metastatic Castrate Resistant Prostate Cancer (metCRPC). J Clin Oncol 2010; 28 (Suppl.): Abst TPS247
83. 177Lu-J591) and ketoconazole in patients (pts) with high-risk castrate biochemically relapsed prostate cancer (PC) after local therapy. J Clin Oncol 2010; 28 (Suppl.): Abst TPS248
84. Ryan C, Efstathiou E, Smith M, et al,. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol 2009; 27: 5046
85. Danila DC, Morris MJ, de Bono JS, et al,. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-501
86. De Bono J, Logothetis CJ, Fizazi K, et al,. Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): results of COU-AA-301, a randomized, double-blind, placebo-controlled phase III study. 35th ESMO Congress. 2010; Abstract LBA5
87. Papandreou C, Daliani D, Thall P, et al,. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20: 3072-80 (Pubitemid 34791096)
88. Petrioli R, Pascucci A, Francini E, et al,. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int 2007; 100: 775-9 (Pubitemid 47360167)
89. Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM,. A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs 2010; 21: 433-8
90. de Bono J, Oudard S, Ozguroglu M, et al,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
91. Sartor AO, Petrylak DP, Witjes JA, et al,. Satraplatin in patients with advanced hormone-refractory prostate cancer (HRPC): overall survival (OS) results from the phase III satraplatin and prednisone against refractory cancer (SPARC) trial. J Clin Oncol 2008; 26: 5003 (Meeting Abstracts)
92. Rosenberg JE, Weinberg VK, Kelly WK, et al,. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-63 (Pubitemid 47106144)
93. Harzstark AL, Rosenberg JE, Weinberg VK, et al,. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the department of defense prostate cancer clinical trials consortium. Cancer 2010; [Epub ahead of print]. DOI: 10.1002/cncr.25810
94. Beardsley EK, Saad F, Eigl B, et al,. A phase II study of patupilone in patients (pts) with metastatic castration- resistant prostate cancer (CRPC) who have progressed after docetaxel. J Clin Oncol 2009; 27: 5139 (Meeting Abstracts)
95. Rosenberg J, Galsky M, Rohs N, et al,. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006; 106: 58-62 (Pubitemid 43033322)
96. Saad F, Gleason D, Murray R, et al,. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68
97. Saad F, Gleason D, Murray R, et al,. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-82 (Pubitemid 38807610)
98. Small E, Smith M, Seaman J, Petrone S, Kowalski M,. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003; 21: 4277-84 (Pubitemid 46621802)
99. Ernst D, Tannock I, Winquist E, et al,. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-42 (Pubitemid 46613484)
100. Fizazi K, Carducci MA, Smith MR, et al,. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2010; 28: 18s (LBA4507) (Meeting Abstracts)
101. Sciuto R, Festa A, Rea S, et al,. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 2002; 43: 79-86 (Pubitemid 34101193)
102. Tu S, Millikan R, Mengistu B, et al,. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357: 336-41 (Pubitemid 32128538)
103. Akerley W, Butera J, Wehbe T, et al,. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 2002; 94: 1654-60 (Pubitemid 34241101)
104. Han S, de Klerk J, Tan S, et al,. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002; 43: 1150-6 (Pubitemid 34988760)
105. Fizazi K, Beuzeboc P, Lumbroso J, et al,. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2429-35
106. Palmedo H, Manka-Waluch A, Albers P, et al,. Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 2003; 21: 2869-75 (Pubitemid 46621835)
107. Nilsson S, Franzen L, Parker C, et al,. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007; 8: 587-94 (Pubitemid 46995621)
108. Smith MR, Egerdie B, Hernandez Toriz N, et al,. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745-55
109. Silberstein E, Eugene L, Saenger S,. Painful osteoblastic metastases: the role of nuclear medicine. Oncology 2001; 15: 157-63 (Pubitemid 33739474)
110. Moore MJ, Osoba D, Murphy K, et al,. Use of palliative end points to evaluate the effects of mitoxantrane and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994; 12: 689-94 (Pubitemid 24110906)